Evidence map›Paper›PMID 35996620›Full record

ArticleAdvances and applications in bioinformatics and chemistry : AABC2022

In silico Drug Repurposing of Anticancer Drug 5-FU and Analogues Against SARS-CoV-2 Main Protease: Molecular Docking, Molecular Dynamics Simulation, Pharmacokinetics and Chemical Reactivity Studies.

Aristote Matondo, Washington Dendera, Bienfait Kabuyaya Isamura, Koto-Te-Nyiwa Ngbolua, Hilaire V S Mambo, Mayaliwa Muzomwe, Virima Mudogo

Abstract read
In one paragraph

Article in Advances and applications in bioinformatics and chemistry : AABC, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Bioinformatics Study of Flavonoids From GenusAdvances and applications in bioinformatics and chemistry : AABC · 2024
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aristote MatondoDepartment of Chemistry, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.ORCID 0000-0002-6246-9803
Washington DenderaDepartment of Chemistry, Rhodes University, Makhanda, Eastern Cape, South Africa.ORCID 0000-0002-4179-3508
Bienfait Kabuyaya IsamuraDepartment of Chemistry, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
Koto-Te-Nyiwa NgboluaDepartment of Biology, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
Hilaire V S MamboDepartment of Chemistry, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
Mayaliwa MuzomweDepartment of Chemistry, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
Virima MudogoDepartment of Chemistry, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Since the last COVID-19 outbreak, several approaches have been given a try to quickly tackle this global calamity. One of the well-established strategies is the drug repurposing, which consists in finding new therapeutic uses for approved drugs. Following the same paradigm, we report in the present study, an investigation of the potential inhibitory activity of 5-FU and nineteen of its analogues against the SARS-CoV-2 main protease (3CLpro). Material and Methods: Molecular docking calculations were performed to investigate the binding affinity of the ligands within the active site of 3CLpro. The best binding candidates were further considered for molecular dynamics simulations for 100 ns to gain a time-resolved understanding of the behavior of the guest-host complexes. Furthermore, the profile of druggability of the best binding ligands was assessed based on ADMET predictions. Finally, their chemical reactivity was elucidated using different reactivity descriptors, namely the molecular electrostatic potential (MEP), Fukui functions and frontier molecular orbitals. Results and Discussion: From the calculations performed, four candidates (compounds 14, 15, 16 and 18) show promising results with respect to the binding affinity to the target protease, 3CLpro, the therapeutic profile of druggability and safety. These compounds are maintained inside the active site of 3CLpro thanks to a variety of noncovalent interactions, especially hydrogen bonds, involving important amino acids such as GLU166, HIS163, GLY143, ASN142, HIS172, CYS145. Molecular dynamics simulations suggest that the four ligands are well trapped within the active site of the protein over a time gap of 100 ns, ligand Conclusion: In line with the findings reported herein, we recommend that further in-vitro and in-vivo investigations are carried out to shed light on the possible mechanism of pharmacological action of the proposed ligands.

Indexed as

5-fluorouracilADMETdrug repurposingmolecular dockingmolecular dynamics simulationSARS-CoV-2

Identifiers

PMID35996620
PMCPMC9391940

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.